Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 10Phase 1/2 6Phase 3 4Phase 2/3 2Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 75Lung Neoplasms 48Small Cell Lung Carcinoma 11Neoplasms 10NSCLC 8Colorectal Neoplasms 7Prostatic Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Mesothelioma 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Head and Neck Neoplasms 4Adenocarcinoma of Lung 4Liver Neoplasms 3Hematologic Neoplasms 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Sarcoma 2Recurrence 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Laryngeal Neoplasms 2

Interventions

rofecoxib 1lenvatinib 1Gemcitabine 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Advanced Non-small Cell Lung Cancer × Thoracic × Clear all
NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2/3 Terminated
16 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT00385606 2023-03-23

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

National Cancer Institute, Naples

Phase 2/3 Completed
400 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡